Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies.
Current treatment modalities for cancer combine cytotoxic drugs against DNA and novel targeted drugs affecting signal transduction pathways, which are required for growth progression and metastasizing tumors. Classical chemotherapeutic regimens for gastro-intestinal tumors include antimetabolites based on 5-fluorouracil (5FU), the platinum analog oxaliplatin and the topoisomerase inhibitor irinotecan. The thymidine analog trifluorothymidine (TFT) has been shown to bypass resistance pathways for 5FU derivatives (S-1, UFT, Xeloda) in model systems, while concurrent application with a thymidine phosphorylase inhibitor (TPI) increases the bioavailability of TFT, thereby potentiating the in vivo efficacy of TFT. The formulation TAS-102 is given orally in a 1.0:0.5 molar ratio (TFT:TPI). The formulation is dual-targeted due to the cytotoxic effect of TFT, which is enhanced by TPI, while TPI also exerts antiangiogenic effects by inhibiting thymidine phosphorylase (TP), also known as platelet-derived endothelial cell growth factor. Evidence is accumulating from in vitro and in vivo preclinical studies that these properties favor further combinations with other cytotoxic agents currently being used in the treatment of gastro-intestinal tumors. Also treatment with targeted agents will synergistically down-regulate signal transduction pathways responsible for growth and progression of tumors. In this review, we summarize the available information on (clinical) pharmacology, mechanisms of action, pharmacodynamic and pharmacokinetic properties, early clinical trials and future directions of the new potent combination drug TAS-102.
Temmink
Olaf H
OH
Department of Medical Oncology, VU University Medical Center, Amsterdam 1007 MB, The Netherlands.
Emura
Tomohiro
T
de Bruin
Michiel
M
Fukushima
Masakazu
M
Peters
Godefridus J
GJ
D000284:Administration, Oral; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D001682:Biological Availability; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D016503:Drug Delivery Systems; D019008:Drug Resistance, Neoplasm; D005544:Forecasting; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D011743:Pyrimidines; D011759:Pyrrolidines; D013936:Thymidine / Q000031:analogs & derivatives / Q000494:pharmacology; D013941:Thymine; D014271:Trifluridine / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D014498:Uracil / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use
C506441:5-chloro-6-(2-imino-propyrrolidin-1-yl) methyl-2,4 (1H, 3H)-pyrimidinedione hydrochloride; D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D011743:Pyrimidines; D011759:Pyrrolidines; C000613803:trifluridine tipiracil drug combination; D014498:Uracil; C030986:pyrimidine; D013941:Thymine; D014271:Trifluridine; D013936:Thymidine